Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients
DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren Cohen, MD who previously served as both Fortrea’s chief medical officer (CMO) and president of Clinical Pharmacology Services (CPS) is now dedicated to his CMO responsibilities, namely medical strategy, scientific leadership, ethics and governance oversight across Fortrea’s portfolio. Scott Dove, PhD joins Fortrea as its new president of CPS, responsible for Fortrea’s early clinical development solutions across its global network of clinical research units. Cohen and Dove both serve on Fortrea’s Executive Committee.
“The addition of Scott to the Fortrea team while Oren becomes fully dedicated to the medical and scientific aspects of development is a win for clients,” said Anshul Thakral, CEO. “Working closely with our business leaders across all phases of clinical development, Oren will deepen his relationships with clients. He’s engaging earlier in scientific dialogue and collaborating closely with our physicians and therapeutic leaders to help address complex development challenges, all while upholding the highest standards of scientific integrity and patient safety. Scott is making a fast start with our Clinical Pharmacology team and is getting a first-hand view of our world-class clinics. He combines a strong technical background in clinical development and operations with a successful track record of leadership in building and leading global organizations, and I’m looking forward to his insights on how we further strengthen our offering.”
Oren Cohen, MD Chief Medical Officer
Oren Cohen, MD is a veteran of drug development, bringing more than 20 years of experience in various medical and scientific executive leadership roles in the pharmaceutical industry. Prior to Fortrea, Dr. Cohen served as CMO and head of Clinical Pharmacology Services at Labcorp Drug Development. Previously, he was CMO at Viamet Pharmaceuticals and served in several senior medical and operational leadership positions at Quintiles, now part of IQVIA.
Dr. Cohen received his MD from Duke University and served his internship and residency at The New York Hospital, Cornell Medical Center in New York City. He completed his fellowship in Infectious Diseases at the National Institute of Allergy and Infectious Diseases, where he stayed as a Principal Investigator and served as the institute’s assistant director for medical affairs. He is a Consulting Professor of Medicine at Duke University Medical Center, a member of the Board of Visitors for Duke University School of Medicine and a Fellow of the Infectious Diseases Society of America.
Scott Dove, PhD President Clinical Pharmacology Services
Scott Dove, PhD brings more than 25 years of drug development experience to Fortrea, serving in roles of increasing responsibility at pharma, biotech and CRO companies. Most recently, he has served as an advisor to a variety of companies, including Fortrea. Previously, Dr. Dove was chief operating officer at Aravive, leading R&D operations for a clinical stage, oncology-focused biotech. He also served in leadership roles at PPD for more than a decade, where he led early development services. Dr. Dove also held leadership roles at Allergan and Furiex Pharmaceuticals.
Dr. Dove received his PhD from Texas A&M Health Science Center and earned his bachelor of science in biochemistry at Texas A&M University.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Fortrea Contacts:
Tracy Krumme (Investors) – 984-385-6707, [email protected]
Sue Zaranek (Media) – 919-943-5422, [email protected]
Kate Dillon (Media) – 646-818-9115, [email protected]
GlobeNewswire Distribution ID 9655383